CN102395682B - 肿瘤分级和癌症预后 - Google Patents

肿瘤分级和癌症预后 Download PDF

Info

Publication number
CN102395682B
CN102395682B CN200880114588.6A CN200880114588A CN102395682B CN 102395682 B CN102395682 B CN 102395682B CN 200880114588 A CN200880114588 A CN 200880114588A CN 102395682 B CN102395682 B CN 102395682B
Authority
CN
China
Prior art keywords
mgi
expression level
cancer
patients
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880114588.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102395682A (zh
Inventor
M·G·厄兰德
马小骏
D·斯格罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheranostics Inc
Original Assignee
Aviaradx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviaradx Inc filed Critical Aviaradx Inc
Publication of CN102395682A publication Critical patent/CN102395682A/zh
Application granted granted Critical
Publication of CN102395682B publication Critical patent/CN102395682B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200880114588.6A 2007-09-06 2008-09-06 肿瘤分级和癌症预后 Active CN102395682B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97052907P 2007-09-06 2007-09-06
US60/970,529 2007-09-06
PCT/US2008/075528 WO2009108215A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Publications (2)

Publication Number Publication Date
CN102395682A CN102395682A (zh) 2012-03-28
CN102395682B true CN102395682B (zh) 2015-09-30

Family

ID=40790735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880114588.6A Active CN102395682B (zh) 2007-09-06 2008-09-06 肿瘤分级和癌症预后

Country Status (7)

Country Link
US (3) US9447470B2 (enExample)
EP (1) EP2195467B1 (enExample)
JP (2) JP2010538609A (enExample)
CN (1) CN102395682B (enExample)
CA (1) CA2698569A1 (enExample)
ES (1) ES2618353T3 (enExample)
WO (1) WO2009108215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
EP2648762B1 (en) * 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US20120271553A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
US9470693B2 (en) 2012-05-18 2016-10-18 University Of North Dakota Method for quantifying proteins and isoforms thereof
IN2014MN02418A (enExample) * 2012-05-22 2015-08-14 Nanostring Technologies Inc
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
AU2014317843A1 (en) * 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
US10253369B2 (en) 2014-05-29 2019-04-09 Biotheranostics, Inc. Predicting likelihood of response to combination therapy
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
CN107119055A (zh) * 2017-05-18 2017-09-01 南京中医药大学 分子标志物bub1b基因及其应用
CN110021433B (zh) * 2017-08-30 2023-11-17 中山大学 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN109706160A (zh) * 2019-02-22 2019-05-03 广西医科大学 重组人蛋白激酶Nek2蛋白表达和纯化方法
KR102405973B1 (ko) * 2019-09-20 2022-06-07 고려대학교 산학협력단 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법
KR102508210B1 (ko) * 2020-10-16 2023-03-10 고려대학교 산학협력단 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법
CN115029437A (zh) * 2022-04-28 2022-09-09 深圳市陆为生物技术有限公司 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
WO2000029044A2 (en) 1998-11-13 2000-05-25 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030228575A1 (en) * 2001-01-31 2003-12-11 Yuk Ming Dennis Lo Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers
US20030064385A1 (en) * 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
US20030138793A1 (en) * 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
BRPI0414446A (pt) * 2003-09-18 2006-11-14 Genmab As métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
CA2539107A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US7498693B2 (en) 2004-02-18 2009-03-03 Diversified Technologies, Inc. More compact and higher reliability power source system
CA2608643A1 (en) * 2005-05-13 2006-11-16 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv

Also Published As

Publication number Publication date
JP2015057055A (ja) 2015-03-26
JP2010538609A (ja) 2010-12-16
EP2195467A1 (en) 2010-06-16
US20180291461A1 (en) 2018-10-11
US9447470B2 (en) 2016-09-20
US20210371934A1 (en) 2021-12-02
US12492432B2 (en) 2025-12-09
EP2195467B1 (en) 2016-12-14
US20110136680A1 (en) 2011-06-09
WO2009108215A1 (en) 2009-09-03
CN102395682A (zh) 2012-03-28
CA2698569A1 (en) 2009-09-03
US11021754B2 (en) 2021-06-01
ES2618353T3 (es) 2017-06-21

Similar Documents

Publication Publication Date Title
CN102395682B (zh) 肿瘤分级和癌症预后
US12460265B2 (en) Post-treatment breast cancer prognosis
CN101356532B (zh) 基于基因的算法型癌症预后
US20220186317A1 (en) Predicting breast cancer recurrence
JP2008521383A (ja) p53の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
EP2121988B1 (en) Prostate cancer survival and recurrence
CN109072481B (zh) 早期乳腺癌内分泌治疗后剩余风险的基因特征
EP2419540B1 (en) Methods and gene expression signature for assessing ras pathway activity
CN107614696A (zh) 基因表现图谱以及将其应用于乳癌医疗之方法
EP2780476B1 (en) Methods for diagnosis and/or prognosis of gynecological cancer
Sims et al. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?
JP2020507320A (ja) 前立腺がんにおける後期臨床エンドポイントを評価するためのアルゴリズムおよび方法
WO2015184182A1 (en) Predicting likelihood of response to combination therapy
HK1197803A (en) Post-treatment breast cancer prognosis
HK1127413A (en) Gene-based algorithmic cancer prognosis
AU2014318859A1 (en) Predicting breast cancer recurrence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant